Successful Treatment of Perioral Dermatitis with Upadacitinib
Main Article Content
Keywords
perioral dermatitis, Janus kinase inhibitor, upadacitinib
Abstract
Perioral dermatitis (POD) is a benign, chronic inflammatory skin condition characterized by small papules, pustules, and erythematous scaly patches around the perioral region. Treatment is not reliably effective, and the condition can be prolonged. We herein report a case of the successful treatment of perioral dermatitis (POD) using upadacitinib. A 45-year-old female with a history of rosacea, presented to the clinic with a 2-3-year history of severely pruritic erythematous papules around the chin and mouth, consistent with POD. Our study demonstrates that Janus kinase inhibitors are a promising therapeutic modality for this condition.
References
2. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2018;76: 736-744.
3. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;2015(7):CD009864.
4. Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci.
2024;17(1):e13688.
5. Teng Y, Ren M, Ding Y, Yang X, Fan Y, Tao X. A Case of Perioral Dermatitis Successfully Treated with Abrocitinib. Clin Cosmet Investig Dermatol. 2023;16:3035-3038.
6. Swenson K, Stern A, Graber E. A Retrospective Review of a Cohort of Patients with Periorificial Dermatitis Treated with Sarecycline. J Clin Aesthet Dermatol. 2024 Jun;17(6):50-54.
7. Crowley EL, Nezamololama N, Papp K, Gooderham MJ. Abrocitinib for the treatment of atopic dermatitis. Expert Rev Clin Immunol. 2020;16(10):955-962.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.